Steik Jason Paul 4

What Happened

• Jason Paul Steik, Chief Clinical Officer of Pennant Group, was granted 26,000 shares on March 5, 2026. The grant is reported at $33.30 per share, for a total reported value of $865,800. The transaction is reported as a derivative award (code A), not an open-market purchase or sale.

Key Details

• Transaction date and price: March 5, 2026; 26,000 shares at $33.30 each (total $865,800).
• Vesting: These shares vest in five equal annual installments beginning March 5, 2027 (footnote F1).
• Shares owned after transaction: Not specified in the filing.
• Filing timeliness: Form 4 was filed late due to an inadvertent administrative error; the late filing delays public disclosure but does not change the grant itself.

Context

• This was an equity award/grant (derivative), typically time-vesting (not an immediate open-market purchase or sale). Such awards are common compensation practices and do not, by themselves, indicate insider intent to buy or sell shares.
• No indication in the filing of a sale, exercise-for-cash, tax-withholding, or 10b5-1 plan.